PharmaShots | Incisive News in 3 Shots

Subscribe Now

Multiple Myeloma

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Mult...

May 2, 2022

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

October 13, 2021

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

August 30, 2021

$BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma$

BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma

August 20, 2021

C4T's CFT7455 Receives the US FDA's Orphan Drug designation for the Treatment of Multiple Myeloma

C4T's CFT7455 Receives the US FDA's Orphan Drug designation for the Treatment of Multiple Myeloma

August 12, 2021

Janssen's Darzalex Faspro (daratumumab and hyaluronidase-fihj) + Pomalidomide and Dexamethasone Receive the US FDA's Approval to Treat Patients with Multiple Myeloma

Janssen's Darzalex Faspro (daratumumab and hyaluronidase-fihj) + Pomalidomide and Dexamethasone Receive the US FDA's Approval to T...

July 13, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us